Albumin-based nanoparticles: a promising strategy to overcome cancer drug resistance
Discontinue if: Significant adverse reactions occur, you achieve body composition goals, no response after 8-12 weeks at optimal dosing, medical contraindications develop, or pregnancy occurs
Brand: Neurogan Health
Kostyuk VA, Potapovich AI, Cesareo E, Brescia S, Guerra L, Valacchi G, Pecorelli A, Deeva IB, Raskovic D, De Luca C, Pastore S, Korkina LG (2010) Dysfunction of glutathione S-transferase leads to excess 4-hydroxy-2-nonenal and H 2 O 2 and impaired cytokine pattern in cultured keratinocytes and blood of vitiligo patients
Phase II study of single-agent panitumumab in patients with incurable cutaneous squamous cell carcinoma